Initial disease severity and methimazole titration for Graves' disease: a retrospective longitudinal cohort study
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgag134 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Aaron Hayden Smith und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Methimazole, Graves Disease, Antithyroid Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Context
Graves' disease (GD) is the most common cause of thyrotoxicosis. Medical therapy with methimazole is the most common way to treat GD, but it has a narrow and dynamic therapeutic index, requiring frequent monitoring for titration. It is unclear how much initial disease severity (IDS) affects titration patterns.
Objective
Identify associations between IDS with methimazole dose and thyrotoxicosis control after initiation of therapy.
Design
Retrospective longitudinal cohort study (2018-2024).
Setting
A single tertiary medical center. Patients or Other Participants The study included 152 patients, aged 18 years and older, diagnosed with GD. It encompassed 1432 encounters. Main Outcome Measure(s) The analysis focused on the association of IDS, age, and sex with average decrease in methimazole dose per encounter, biochemical thyroid status per encounter, time until first euthyroid encounter, and dose of methimazole after 180 days of treatment.
Results
IDS was positively associated with percentage dose reduction of methimazole per encounter (P = .012) and proportion of hypothyroid encounters (P = .0101). There was no association of IDS with the proportion of hyperthyroid encounters (P = .088), methimazole dose after 180 days (P = .222), nor time to first encounter with euthyroid status. Age and sex were not associated with changes in dose or biochemical thyroid status.
Conclusion
When given a larger dose of methimazole, patients with severe thyrotoxicosis from GD reach euthyroid status as quickly as other patients with GD. However, these patients have more lability in thyroid control and may benefit from more frequent monitoring. After 6 months, severity of initial thyrotoxicosis was not associated with methimazole dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Department of Medicine, Division of Endocrinology and Metabolism, Franciscan Health Indianapolis, Indianapolis, IN 46237, USA.
ORCID-Profile: Aaron Hayden Smith, Michael Morkos
Zitieren
APA
Smith, A. H., Priscu, A., & Morkos, M. (2026). Initial disease severity and methimazole titration for Graves' disease: a retrospective longitudinal cohort study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag134
Vancouver
Smith AH, Priscu A, Morkos M. Initial disease severity and methimazole titration for Graves' disease: a retrospective longitudinal cohort study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag134
BibTeX
@article{Smith2026,
author = {Smith, Aaron Hayden and Priscu, Adelina and Morkos, Michael},
title = {Initial disease severity and methimazole titration for Graves' disease: a retrospective longitudinal cohort study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag134}
}
EUVIMED